Form 4: Denali Therapeutics CEO Reports Stock Transaction
Insider Transaction (Form 4)
Ryan J. Watts, President and CEO and a Director of Denali Therapeutics Inc., reported a transaction in 32,220 shares of common stock on August 12, 2026.
Summary
- Bona fide gift: disposed of 32,220 Common Stock on August 12, 2026; holds 2,120,384 after (Indirect).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Ryan J. Watts — Director, Officer (President and CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-12 | Bona fide gift | Common Stock | 32,220 | — | — | 2,120,384 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-12 | Bona fide gift (32,220 shares) |
Keywords
insider transaction, Form 4, DNLI, Denali Therapeutics Inc., neutral, Ryan J. Watts
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.